. 2020 Sep 16;9(10):999–1008. doi: 10.1530/EC-20-0420
This work is licensed under a Table 3.
Univariate analysis of the factors associated with BRAF V600E in primary tumors and LNM.
| Characteristics | BRAF V600E in primary tumors | BRAF V600E in LNM | ||||
|---|---|---|---|---|---|---|
| WT (n = 66) | Mutation (n = 300) | P | WT (n = 79) | Mutation (n = 287) | P | |
| Age at diagnosis (years) | ||||||
| <55 | 59 (18.3) | 264 (81.7) | 0.117 | 67 (20.7) | 256 (79.3) | 0.283 |
| ≥55 | 7 (16.3) | 36 (83.7) | 12 (27.9) | 31 (72.1) | ||
| Sex | ||||||
| Female | 44 (18.6) | 192 (81.4) | 0.682 | 53 (22.5) | 183 (77.5) | 0.584 |
| Male | 22 (16.9) | 108 (83.1) | 26 (20.0) | 104 (80.0) | ||
| Family history | ||||||
| No | 65 (18.5) | 287 (81.5) | 0.480 | 78 (22.2) | 274 (77.8) | 0.318 |
| Yes | 1 (7.1) | 13 (92.9) | 1 (7.1) | 13 (92.9) | ||
| Histologic variants (PTC) | ||||||
| Classic | 60 (16.9) | 295 (83.1) | 71 (20.0) | 284 (80.0) | ||
| Follicular | 1 (25.0) | 3 (75.0) | 0.007 | 2 (50.0) | 2 (50.0) | 0.000 |
| Other variants | 5 (71.4) | 2 (28.6) | 6 (85.7) | 1 (14.3) | ||
| Tumor size (cm) | ||||||
| <2 | 44 (15.6) | 238 (84.4) | 0.018 | 55 (19.5) | 227 (80.5) | 0.139 |
| ≥2 | 21 (27.3) | 56 (72.7) | 21 (27.3) | 56 (72.7) | ||
| Multifocality | ||||||
| Unifocal | 41 (23.2) | 136 (76.8) | 0.012 | 43 (24.3) | 134 (75.7) | 0.106 |
| Multifocal | 24 (13.0) | 160 (87.0) | 32 (17.4) | 152 (82.6) | ||
| Lesion location | ||||||
| Unilateral | 40 (21.6) | 145 (78.4) | 0.071 | 49 (26.5) | 136 (73.5) | 0.021 |
| Bilaterality | 26 (14.4) | 155 (85.6) | 30 (16.6) | 151 (83.4) | ||
| Extrathyroidal extension | ||||||
| No | 44 (18.2) | 198 (81.8) | 50 (20.7) | 192 (79.3) | ||
| Minimal | 14 (14.4) | 83 (85.6) | 0.191 | 18 (18.6) | 79 (81.4) | 0.039 |
| Gross | 8 (29.6) | 19 (70.4) | 11 (40.7) | 16 (59.3) | ||
| Capsular invasion | ||||||
| No | 30 (18.2) | 135 (81.8) | 0.964 | 33 (20.0) | 132 (80.0) | 0.489 |
| Yes | 36 (18.0) | 164 (82.0) | 46 (23.0) | 154 (77.0) | ||
| N stage | ||||||
| N1a | 31 (16.8) | 154 (83.2) | 0.521 | 36 (19.5) | 149 (80.5) | 0.318 |
| N1b | 35 (19.3) | 146 (80.7) | 43 (23.8) | 138 (76.2) | ||
| Number of LNM | ||||||
| ≤5 | 28 (13.5) | 179 (86.5) | 0.009 | 37 (17.9) | 170 (82.1) | 0.042 |
| >5 | 38 (24.2) | 119 (75.8) | 42 (26.8) | 115 (73.2) | ||
| Size of the largest metastatic focus to LNM (cm) | ||||||
| <0.65 | 25 (11.0) | 202 (89.0) | 0.000 | 31 (13.7) | 196 (86.3) | 0.000 |
| ≥0.65 | 40 (30.5) | 91 (69.5) | 46 (35.1) | 85 (64.9) | ||
| Extranodal extension | ||||||
| No | 38 (15.8) | 203 (84.2) | 0.118 | 48 (19.9) | 193 (80.1) | 0.282 |
| Yes | 28 (22.4) | 97 (77.6) | 31 (24.8) | 94 (75.2) | ||
| Cumulative iodine dose (MBq) | ||||||
| 0 | 7 (12.5) | 49 (87.5) | 14 (25.0) | 42 (75.0) | ||
| ≤5550 | 39 (18.4) | 173 (81.6) | 0.460 | 40 (18.9) | 172 (81.1) | 0.332 |
| >5550 | 20 (20.4) | 78 (79.6) | 25 (25.5) | 73 (74.5) | ||
| Distant metastasis | ||||||
| No | 59 (16.6) | 296 (83.4) | 0.000 | 71 (20.0) | 284 (80.0) | 0.000 |
| Yes | 7 (63.6) | 4 (36.4) | 8 (72.7) | 3 (27.3) | ||
| Response to therapy | ||||||
| Excellent response | 26 (13.9) | 161 (86.1) | 0.394 | 34 (18.2) | 153 (81.8) | 0.106 |
| Not cureda | 40 (22.3) | 139 (77.7) | 45 (25.1) | 134 (74.9) | ||
aNot cured include Indeterminate, Biochemical and Structural incomplete response.
PTC, papillary thyroid cancer; LNM, lymph node metastasis; WT, wild type.